How This CRISPR Biotech Could Make Investors Rich Post author:Sam Post published:December 26, 2017 Post category:BioPharma A look at a biotech company that represents a solid trend in the industry. Source: BioSpace You Might Also Like Sarepta Under Pressure As Marathon Pharma Emflaza's Wins FDA Approval for DMD February 9, 2017 All Systems Go: Johnson & Johnson Reaches Out for Second Ionis GI Drug November 15, 2017 Bristol-Myers Squibb Inks Two Separate Pacts With Biogen and Roche For a Total of Up to $1.1B April 12, 2017
Bristol-Myers Squibb Inks Two Separate Pacts With Biogen and Roche For a Total of Up to $1.1B April 12, 2017
